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DNA nonhomologous end-joining (NHEJ)
is a predominant pathway of DNA double-
strand break repair in mammalian cells,
and defects in it cause radiosensitivity at
the cellular and whole-organism levels.
Central toNHEJ is the protein complex con-
taining DNA Ligase IV and XRCC4. By
searching for additional XRCC4-interacting
factors, we identified a previously unchar-
acterized 33 kDa protein, XRCC4-like factor
(XLF, also named Cernunnos), that has
weak sequence homology with XRCC4
and is predicted to display structural simi-
larity to XRCC4. We show that XLF directly
interacts with the XRCC4-Ligase IV com-
plex in vitro and in vivo and that siRNA-
mediated downregulation of XLF in human
cell lines leads to radiosensitivity and im-
paired NHEJ. Furthermore, we establish
that NHEJ-deficient 2BN cells derived
from a radiosensitive and immune-deficient
patient lack XLF due to an inactivating
frameshift mutation in its gene, and that re-
introduction ofwild-typeXLF into such cells
corrects their radiosensitivity andNHEJ de-
fects. XLF thus constitutes a novel core
component of the mammalian NHEJ appa-
ratus.
INTRODUCTION
The DNA double-strand break (DSB) is probably the most
cytotoxic cellular lesion known, with as little as one unre-
paired DSB being capable of triggering programmed cell
death (Rich et al., 2000). DSBs are the principle cytotoxic le-sions generated by ionizing radiation (IR) and radiomimetic
chemicals, can be caused by mechanical stress on chromo-
somes, and also arise when DNA replication forks encounter
other lesions such as DNA single-strand breaks (Khanna and
Jackson, 2001; Mills et al., 2003). Despite posing threats to
genomic integrity, DSBs are nonetheless sometimes gener-
ated deliberately for a defined biological purpose. A good ex-
ample of this is provided by V(D)J recombination, which
takes place in developing B and T lymphocytes to provide
the basis for the antigen binding diversity of the vertebrate
adaptive immune system (reviewed in Gellert [2002]). Nota-
bly, inefficient or inaccurate repair of programmed or sponta-
neously arising DSBs can lead to mutations, dicentric or
acentric chromosomal fragments and/or chromosomal
translocations; and in some cases these have oncogenic po-
tential (Difilippantonio et al., 2002; Ferguson and Alt, 2001;
Khanna and Jackson, 2001; Mills et al., 2003).
There are two principle pathways for DNA DSB repair: ho-
mologous recombination (HR) and nonhomologous end-
joining (NHEJ). These pathways are largely distinct from
one another and function in complementary ways to bring
about DSB repair (Haber, 2000). During HR, the damaged
chromosome enters into synapsis with an undamaged
DNA molecule with which it shares extensive sequence ho-
mology: usually its sister chromatid (reviewed in Modesti and
Kanaar [2001]; West, 2003). By contrast, NHEJ does not re-
quire a homologous undamaged partner DNA molecule and
moreover does not need extensive sequence homologies
between the recombining DNA ends (for reviews see Lieber
et al. [2003] and Weterings and Van Gent [2004]). However,
while its ability to ligate essentially any two DNA ends makes
NHEJ a very effective pathway of DSB repair, some end-pro-
cessing is normally required before ligation, making NHEJ an
intrinsically mutagenic repair mechanism. Reflecting the key
importance of the NHEJ apparatus, mammalian cells bear-
ing defects in core NHEJ components exhibit pronounced
hypersensitivity toward IR and other agents that cause
DSBs but not toward agents that yield other types of DNA le-
sions (reviewed in Lieber et al. [2004]). When such NHEJ de-
fects are manifested at the whole-animal level, they are also
usually associated with defective V(D)J recombination and/
or immunoglobulin class-switch recombination, causingCell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 301
severe combined immune-deficiency or related immunode-
ficiencies (Ferguson and Alt, 2001; Lieber et al., 2004).
At the heart of the NHEJ apparatus in all eukaryotes stud-
ied is the enzyme DNA Ligase IV, which directly mediates
DNA-strand joining by this pathway (Robins and Lindahl,
1996). In addition to possessing a canonical DNA ligase cat-
alytic domain, Ligase IV is distinct from other eukaryotic DNA
ligases in that it possesses two tandemC-terminal BRCT do-
mains. A key development in our understanding of Ligase IV
was the discovery that it exists in a tight complex with the
38 kDa ‘‘adaptor’’ protein XRCC4 (Critchlow et al., 1997;
Grawunder et al., 1997; Herrmann et al., 1998), deficiency
in which also causes marked NHEJ defects (Li et al.,
1995). Structural studies have revealed that XRCC4 contains
a globular N-terminal ‘‘head’’ domain—which might interact
with other proteins and/or DNA—and a protruding helical
coiled-coil region that contains a motif that interacts directly
with the linker region between the two BRCT domains of Li-
gase IV (Grawunder et al., 1998b; Junop et al., 2000; Si-
banda et al., 2001). XRCC4 is tightly associated with Ligase
IV in vivo and is required for its stability (Bryans et al., 1999).
Furthermore, it has been shown that XRCC4 stimulates Li-
gase IV adenylation and overall activity in vitro and in vivo
(Grawunder et al., 1997; Grawunder et al., 1998a; Modesti
et al., 1999). Subsequently, it was shown that targeted inac-
tivation of the genes for Ligase IV or XRCC4 in mouse cells
leads to radiosensitivity and NHEJ defects (Barnes et al.,
1998; Frank et al., 1998) and that human patients with in-
herited hypomorphic mutations in Ligase IV are radiosensi-
tive and also display varying degrees of immune deficiency
(O’Driscoll et al., 2001; Riballo et al., 1999).
A striking feature of the Ligase IV-XRCC4 complex is that it
functions in NHEJ but not in other DNA repair pathways. This
specificity reflects the fact that, despite having an intrinsic
capability to bind DNA, the XRCC4-Ligase IV complex is in-
effective at recognizing DSBs alone and needs to be physi-
cally recruited to these sites by other NHEJ components
(McElhinny et al., 2000; Teo and Jackson, 2000). Two
such proteins are the heterodimeric DNA-end binding pro-
tein Ku and the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs), with which Ku associates (Smith and
Jackson, 1999). The Ku heterodimer forms a ring-like struc-
ture, which binds to DNA ends and has been proposed to ini-
tiate the NHEJ process. Upon DNA-PKcs recruitment, Ku
translocates inward and potentially allows DNA-PKcs to
bridge the broken DNA ends and promote ligation by Ligase
IV-XRCC4 (reviewed in Hefferin and Tomkinson [2005]). In-
deed, the XRCC4-Ligase IV complex can interact with Ku
and DNA-PKcs in vitro (Chen et al., 2000; Hsu et al., 2002;
Kysela et al., 2003), and XRCC4 is phosphorylated by
DNA-PKcs, although any functional relevance for this phos-
phorylation event remains elusive (Critchlow et al., 1997;
Leber et al., 1998). Other proteins implicated in mammalian
NHEJ are as follows: Artemis, whose nuclease function is
thought to aid the processing of V(D)J recombination inter-
mediates and certain radiation-induced lesions before they
are ligated (Moshous et al., 2001); DNA polymerases of the
Pol X family that are thought to mediate strand-filling steps302 Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc.in the pathway (for example, Ma et al. [2004]); and polynucle-
otide kinase that modifies certain DNA terminal structures to
permit their subsequent ligation (Chappell et al., 2002; Koch
et al., 2004).
Although the above factors seem in principle capable of
carrying out all the known steps of NHEJ and promote liga-
tion in vitro, it has recently become apparent that at least one
additional core NHEJ component in vivo remains to be iden-
tified. Thus, work on 2BN cells—derived from a radiosensi-
tive and immune-deficient patient—has revealed them to
display a marked NHEJ deficiency that cannot be ascribed
to defects in any of the known NHEJ components (Dai
et al., 2003). With this in mind, we carried out searches for
factors that bind to established NHEJ components. Herein,
we describe the identification of one such human protein,
XLF, and demonstrate that it not only corresponds to a new
core NHEJ component but is, in fact, the factor mutated in
2BN cells. Based on our biochemical observation that XLF
interacts with the Ligase IV-XRCC4 complex and our find-
ings that XLF is required for efficient repair of DNA DSBs in
vivo, we discuss the likely mechanisms by which XLF pro-
motes effective DSB repair in mammalian cells.
RESULTS
Yeast Two-Hybrid Screening for XRCC4 Interactors
Due to the pivotal role of XRCC4 in NHEJ, we searched for
further XRCC4-interacting proteins. Thus, we conducted
a LexA-based yeast two-hybrid screen with full-length
XRCC4 as bait (see Experimental Procedures for details).
The screen yielded 78 positive clones, out of which we
have currently examined 25. Two of these positive and
bait-dependent cDNA clones encoded Aprataxin, which
has recently been reported to interact with XRCC4 (Clem-
ents et al., 2004). Two further cDNA clones corresponded
to N-terminal portions of an as-yet-uncharacterized human
open reading frame (FLJ12610) that encodes a predicted
full-length protein of 33 kDa (Figure 1A). As shown in
Figure 1B, the 299 residue FLJ12610 protein is well con-
served throughout vertebrate species, with stretches of par-
ticularly high sequence conservation in its N-terminal region
(residues 34–79) and its middle portion (residues 120–205).
The encoded protein also contains a putative nuclear local-
ization sequence at its very C terminus (KRKK).
XLF (FLJ12610) Is Predicted to Display Structural
Similarity to XRCC4
Standard sequence homology and motif searches failed to
identify any FLJ12610-related proteins other than the family
of its vertebrate orthologs. Strikingly, however, sequence
structure comparisons with either the Fugue algorithm
(http://www-cryst.bioc.cam.ac.uk/fugue/; Shi et al., 2001)
or the 3D-PSSM algorithm (Fold recognition server, http://
www.sbg.bio.ic.ac.uk/3dpssm/; Kelley et al., 2000) indi-
cated that the FLJ12610 protein very likely displays a similar
structural organization to XRCC4 (Figure 1C; see Table S1
and Figure S1 in the Supplemental Data available with this
article online). Indeed, when FLJ12610 and its vertebrate
Figure 1. XLF, a Conserved 33 kDa Protein, Interacts with XRCC4 in a Yeast Two-Hybrid Screen and Is Predicted to Show Struc-
tural Similarity to XRCC4
(A) Schematic representation of full-length XLF and two cDNA clones identified from a yeast-two hybrid screen with full-length XRCC4 as bait. Out of 75
interacting clones, two (gray) were identified as encoding the N-terminal region of FLJ12610 (XLF). Above is a representation of full-length XLF, with pre-
dicted head, coiled-coil, and nuclear localization sequence (NLS) indicated.
(B) XLF is conserved throughout vertebrates. Alignment (Multalin, http://prodes.toulouse.inra.fr/mutalin/mutalin.html) of human XLF (FLJ12610) and homo-
logs in other representative eukaryotes.
(C) XLF is predicted to display structural homology to XRCC4. Left: comparative structural modeling of the XLF secondary structure based on the structure
of XRCC4 (PDB: 1fu1 and 1ik9, http://swissmodel.expasy.org/). Right: XRCC4 dimer structural coordinates (PDB: 1fu1) visualized using MacPyMOL.
(D) XLF localizes to the nucleus. Confocal images: top, U2OS cells were fixed and stained with rabbit anti-XLF polyclonal antibody, together with TOTO3 dye
to visualize DNA. Bottom, U2OS cells were transfected with GFP-XLF and fixed 24 hr afterwards.family members were compared to the secondary structure
and fold databases of these algorithms, FLJ12610 homo-
logswere predictedwith high confidence to adopt a fold sim-
ilar to the structure solved for XRCC4 (Fugue, Z score 4.75
and 4.0, 95% confidence; 3D-PSSM, E value 0.027, 95%
confidence). Specifically, this analysis suggested that, like
the similarly-sized XRCC4 protein, FLJ12610 encodes a
protein containing anN-terminal ‘‘head’’ domain, with the re-
mainder of the protein adopting a coiled-coil structure (Fig-
ure 1C). In line with these predictions, sequence compari-
sons revealed a low level of sequence similarity between
FLJ12610 and XRCC4, particularly in the region of XRCC4
that is believed to interact with Ligase IV. In light of thesefindings and our other data linking FLJ12610 to XRCC4
(see below), we have given it the name ‘‘XRCC4-like factor’’
(XLF).
XLF Is a Nuclear Protein Expressed
in Human Cell Lines
To further study XLF, we raised a rabbit polyclonal antibody
against the full-length recombinant protein and used this to
examine XLF expression. Thus, we established that XLF is
present in a wide range of human cell lines (Figure 4B and
data not shown). Furthermore, indirect immunofluorescence
staining revealed that XLF, like XRCC4, localizes primarily
to the nucleus of human cells (Figure 1D, top). ConsistentCell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 303
with these findings, we found that a green fluorescent
protein (GFP)-XLF fusion was primarily nuclear (Figure 1D,
bottom).
XLF Interacts with XRCC4 and DNA Ligase IV
In Vitro and In Vivo
The identification of XLF by a yeast two-hybrid screen for
XRCC4 interactors suggested that XLF might functionally
cooperate with the XRCC4-DNA Ligase IV complex. To be-
gin to explore this possibility, we generated a glutathione
S-transferase (GST)-XLF fusion protein in bacteria, purified
this, and then used it in protein interaction studies. Thus,
we found that GST-XLF efficiently retrieved both XRCC4
and Ligase IV from HeLa nuclear extract (HNE), whereas it
did not bind the DNA repair and checkpoint factor Mre11
(Figure 2A) nor various other proteins analyzed (Rad50,
DNA-PKcs, and SMC1; data not shown). These interactions
between XLF and the XRCC4-Ligase IV were unlikely to be
mediated by small amounts of DNA in the extract, as the ex-
periments were carried out in the presence of 50 mg/ml
ethidium bromide, which disrupts the majority of protein-
DNA interactions. Furthermore, we found that GST-XLF
pull-downs can quantitatively deplete extracts of virtually all
XRCC4 and Ligase IV (data not shown).
To test whether XLF can interact with the XRCC4-Ligase
IV complex in vivo, we transfected 293T cells with a vector
directing the expression of HA epitope-tagged XLF, made
extracts from these, and tested for the presence of HA-
XLF, XRCC4, and Ligase IV in anti-HA immunoprecipitates.
As shown in Figure 2B, XRCC4 and Ligase IV indeed coim-
munoprecipitated with HA-XLF but were not present in con-
trol immunoprecipitates with anti-GFP antibodies, nor were
they found in HA-immunoprecipitates from extracts of cells
transfected with the parental vector (pCDNA3.1). Moreover,
we established that endogenous XLF in HNE is associated
with XRCC4 (Figure 2C) and Ligase IV (Figure 2D), as both
these proteins were specifically coimmunoprecipitated with
the rabbit anti-XLF antibody. The XRCC4-XLF interaction
was also confirmed in reciprocal immunoprecipitations with
a mouse anti-XRCC4 antibody (Figure 2E). Interestingly,
we found as a result of cotransfection studies that HA-
tagged XLF could be immunoprecipitated with an anti-
FLAG epitope-tag antibody when it was expressed in cells
together with FLAG-tagged XLF (Figure 2F; no HA-XLF
was precipitated by anti-FLAG antibody in the absence of
FLAG-XLF; data not shown). This suggests that multiple
XLF proteins interact with the XRCC4-Ligase IV complex
and/or that XLF can exist as multimers, as is the case for
XRCC4 itself (Junop et al., 2000; Lee et al., 2000; Modesti
et al., 2003). Taken together, the above data reveal that
XLF behaves as a bona fide component of the XRCC4-
Ligase IV complex.
Downregulation of XLF in Human Cell Lines Causes
Marked Radiosensitivity
In light of the above data, we speculated that XLF might be
involved in the NHEJ pathway of DSB repair. To test this
idea, we developed two independent siRNA double-304 Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc.stranded oligonucleotides that target XLF—XLFsi(1) and
XLFsi(2)—and showed that each was capable of efficiently
downregulating XLF protein levels in human U2OS cells
(Figure 3A, top and bottom panels). As a control for subse-
quent studies, we used an siRNA oligonucleotide that effi-
ciently downregulated XRCC4 (Figure 3A, top). Downregula-
tion of XRCC4 also led to decreased Ligase IV levels, which
confirms previous reports indicating that XRCC4 is required
for normal Ligase IV protein stability (Bryans et al., 1999;
Teo and Jackson, 2000). Strikingly, we found that cells
downregulated for XLF were markedly more radiosensitive
than cells downregulated with control siRNA oligonucleo-
tides (Figure 3B). Moreover, the radiosensitivity of XLF-
depleted cells was equivalent to that of cells downregulated
for XRCC4 (Figure 3B). In line with the above findings, we
found that downregulation of XLF also sensitized cells to
Bleocin, a drug that generates a high yield of DNA DSBs;
and again, the degree of sensitization caused by XLF deple-
tion was similar to that achieved by XRCC4 downregulation
(Figure 3C). Taken together, these results indicate that XLF is
required for cellular survival in response to DSB-generating
agents and furthermore support the contention that XLF
and XRCC4 function in the same pathway.
Downregulation of XLF in Human Cell Lines Causes
a Defect in DNA DSB Repair
NHEJ is a predominant DSB pathway in mammalian cells
and is crucial for the efficient random integration of plasmid
DNA into the genome of human tissue culture cells (Lou
et al., 2004). Consistent with this, we found that random
plasmid integration wasmarkedly impaired in cells downreg-
ulated for XRCC4 (Figure 3D). Moreover, downregulation of
XLF reduced integration efficiencies to levels comparable
to those caused by XRCC4 depletion (Figure 3D). These find-
ings strongly suggested that XLF, like XRCC4, is crucial for
DNA DSB repair by NHEJ. To verify this, we used pulsed-
field gel electrophoresis (PFGE) to monitor the repair of IR-
induced DSBs in vivo. Thus, we transfected U2OS cells
with siRNAs targeting XLF, XRCC4, or GFP, and after allow-
ing time for protein downregulation, we treated the cells with
80 Gy of IR. While cells transfected with the control siRNA
were able to repair most DSBs quickly after irradiation (loss
of the faster-migrating DNA signal), cells downregulated for
XLF or XRCC4 displayed much higher levels of broken
DNA molecules migrating into the gel, and this was the
case both at early and later time points (Figure 3E). These
data therefore indicate that both XLF and XRCC4 are re-
quired for normal DNA NHEJ as measured by this assay.
To further study the requirement of XLF for DSB repair, we
analyzed the phosphorylation of histone H2AX on Ser 139
(gH2AX) in response to IR. It has previously been established
that phosphorylation of H2AX correlates with DSB formation
(Rogakou et al., 1998) and that by measuring the extent of
phosphorylation or nuclear foci formation of gH2AX after ra-
diation, one can obtain a fairly accurate assessment of the
extent of DSB repair (for example, Kuhne et al. [2004], Mir-
zoeva and Petrini [2001], Rothkamm and Lobrich [2003]).
While phosphorylated H2AX was readily detectable 2 hr after
Figure 2. XLF Interacts with the XRCC4-Ligase IV Complex In Vitro and In Vivo
(A) GST-XLF interacts with XRCC4 and Ligase IV in pull-down experiments. GST pull-downs from 800 mg of HeLa cell nuclear extract (HNE). Purified GST-
XLF or GST alone was bound to glutathione-Sepharose and incubated with HNE in the presence of 50 mg/ml ethidium bromide. Washed beads were
analyzed by immunoblotting with rabbit anti-Ligase IV, rabbit anti-XRCC4, and rabbit anti-MRE11 antibodies, as indicated. Five percent of input material
was analyzed as a control.
(B) HA-XLF interacts with XRCC4 and Ligase IV in 293T cells. Coimmunoprecipitation of XRCC4 and Ligase IV with HA-XLF from 1 mg of 293T whole-cell
extract (WCE). 293T cells were transfected with HA-XLF or empty vector control (pCDNA3.1). Extracts were prepared 20 hr after transfection and precip-
itated with monoclonal mouse anti-HA or mouse anti-GFP antibody. Samples were analyzed by immunoblotting with rabbit anti-Ligase IV, rabbit anti-
XRCC4, and rabbit anti-HA antibodies, as indicated. Ten percent of input material was analyzed as a control.
(C) Endogenous XLF interacts with XRCC4 in HNE. Coimmunoprecipitation of XRCC4 with XLF from 1 mg of HNE. For immunoprecipitation, rabbit pre-
immune (Pi) serum or rabbit anti-XLF (a-XLF) antibody was used. Samples were analyzed by immunoblotting with mouse anti-XRCC4 and affinity purified
rabbit anti-XLF antibody, as indicated. Ten percent of input material was analyzed as a control.
(D) Endogenous XLF interacts with Ligase IV in HNE. Coimmunoprecipitation of Ligase IV with XLF from 1 mg of HNE. For immunoprecipitations, rabbit
preimmune serum or rabbit anti-XLF antibody was used. Samples were analyzed by immunoblotting with rabbit anti-Ligase IV and affinity purified rabbit
anti-XLF antibodies, as indicated. To prevent unspecific crossreactions between the rabbit antibodies, HRP-conjugated protein A was used as secondary
reagent. Ten percent of input material was analyzed as a control.
(E) XRCC4 interacts with endogenous XLF in HNE. Coimmunoprecipitation of XLF with XRCC4 from 5 mg of HNE. For precipitations, mouse anti-XRCC4
antibody or mouse anti-GFP antibody were used. Samples were analyzed by immunoblotting using rabbit anti-Ligase IV, rabbit anti-XRCC4, and affinity-
purified rabbit anti-XLF antibody.
(F) XLF can formmultimeric complexes. Coimmunoprecipitation of HA-XLFwith FLAG-XLF. 293T cells were cotransfected with HA-XLF and FLAG-XLF, and
extracts were prepared 20 hr after transfection. For precipitations from 1 mg of WCE, mouse anti-FLAG antibody or mouse anti-GFP antibody was used.
Samples were analyzed by immunoblotting using affinity-purified HA-HRP conjugated antibody.irradiation in cells transfected with control GFP siRNA oligo-
nucleotides, it disappeared quickly thereafter, and virtually
no phosphorylated H2AX was detected at later time points(Figure 3F). In contrast, cells downregulated for XLF showed
increased levels of H2AX phosphorylation at later time
points, indicating that DSBs are less efficiently repaired inCell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 305
Figure 3. Downregulation of XLF in U2OS Cells Leads to Increased Radiosensitivity, DSB Repair Defects, and Prolonged Phos-
phorylation of Histone H2AX
(A) siRNA-mediated downregulation of XLF and XRCC4 in U2OS cells. Top: cells were transfected with siRNA oligonucleotides and extracts were prepared
72 hr afterwards. Samples were analyzed by immunoblotting with the indicated antibodies. XLFsi(1) and XLFsi(2) are two independent siRNA oligonucle-
otides targeting different regions in the XLF1 open reading frame. GFPsi is a control oligonucleotide targeting GFP. Bottom: U2OS cells were treated with
XLF siRNA or control (GFPsi) siRNA; 72 hr later, cells were fixed and stained with rabbit anti-XLF rabbit polyclonal antibody, together with TOTO3 dye to
visualize DNA. Cells retaining XLF nuclear staining in the bottom left panel presumably escaped XLF downregulation.
(B) XLF downregulation causes radiosensitivity. Clonogenic survival of U2OS cells transfected with GFPsi (-), XLFsi(1) (:), or XRCC4si (B). Cells were
treated with the indicated doses of IR. Data points represent the mean and standard deviation of three independent experiments.
(C) Downregulation of XLF causes hypersensitivity toward the DSB-generating agent, Bleocin. Clonogenic survival of U2OS cells transfected with GFPsi
(-), XLFsi(1) (:), or XLFsi(2) (asterisk) or XRCC4si (B). Cells were treated with the indicated doses of Bleocin for 24 hr. Data represent the mean and stan-
dard deviation of three independent experiments.
(D) Downregulation of XLF or XRCC4 causes a marked defect in random plasmid integration. U2OS cells were transfected with indicated siRNA oligonu-
cleotides 24 hr before transfection with pEYFP-Nuc(Kanr/Neor); 24 hr later, the cells were replated at low density in selective medium, and colonies were
counted 10 days later. Data represent mean and standard deviation of three independent experiments. Values are given as percentages of the integration
efficiency of cells treated with the control Luc siRNA.306 Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc.
the absence of XLF (Figure 3F). Together, these results show
that XLF, like XRCC4, is required for the efficient repair of
DSBs in human cells.
2BN Cells Derived from a Radiosensitive Patient
Lack Detectable XLF Protein
Until a pivotal report by Jeggo and colleagues in 2003 (Dai
et al., 2003), it was widely believed that all factors involved
in the core process of NHEJ had already been identified.
Surprisingly, this report showed that the 2BN cell line derived
from a radiosensitive and immune-deficient patient exhibited
all the hallmarks of NHEJ deficiency yet did not appear to
have a defect in any of the established NHEJ components.
This led to the conclusion that 2BN cells are defective in
an additional, as-yet-uncharacterized NHEJ protein. To
seewhether XLFmight correspond to this factor, we first car-
ried out indirect immunofluorescence staining of 2BN and
control MRC5 or BJ fibroblasts with the anti-XLF antibody.
Notably, while nuclear XLF immunostaining was observed
in MRC5 and BJ cells, this was not the case for 2BN cells
(Figure 4A). Consistent with these findings, immunoblotting
studies detected XLF protein in extracts of various human
cell lines but not in extracts of 2BN cells (Figure 4B). We
did, however, find less XLF in fibroblasts (MRC5 and BJ)
than in other standard cell lines (293T and U2OS). In addi-
tion, we were unable to detect any XLF in IP-Western studies
with the rabbit anti-XLF antibody and extracts prepared from
2BN cells (data not shown). Thus, we conclude that 2BN
cells contain no XLF, or only very low levels of the protein.
2BN Cells Bear an Inactivating Mutation
in the XLF Gene
The above findings raised the possibility that 2BN cells con-
tain a mutation in the XLF gene. To see whether this was in-
deed the case, we prepared mRNA from telomerized 2BN
cells (2BN-hTERT cells) and amplified the XLF mRNA by
RT-PCR. As shown in Figure 4C, although an 900 bp
PCR product was generated from all cell lines tested, we
consistently obtained less product from 2BN cells than
from the other cell lines, possibly indicating a defect in XLF
expression or mRNA stability (such as resulting from non-
sense-mediated mRNA decay). To explore this further, we
cloned XLF cDNAs derived from two independent 2BN
mRNA preparations and sequenced five clones per prepara-
tion. Strikingly, in every one of these sequencing reactions,
there was a thymine insertion in the fourth codon of the
XLF open reading frame (Figure 4C). By contrast, no muta-
tions were ever observed in the XLF open reading frame
when we analyzed PCR products generated from other
cell lines (MRC5, 180BR, MO59J, 1BR, and U2OS; data
not shown). To verify these results, we subsequently ampli-fied the first coding exon of the XLF gene (exon 11,
Figure 4D) from total genomic DNA of 2BN and MRC5 cells.
Amplified DNA was cloned and subjected to sequence anal-
ysis. Again, while all clones derived from MRC5 cells corre-
sponded to the published XLF (FLJ12610) genomic se-
quence, every one of the clones derived from 2BN cells
contained the T insertion (Figure 4D, chromatograms). We
therefore conclude that 2BN cells either bear this mutation
in a homozygous state or carry this mutation on one XLF
allele, with the other XLF allele being deleted. Crucially, the
single base-pair insertion mutation in 2BN cells results in
a translational frameshift in the XLF coding sequence (Fig-
ure 4C), leading to an early STOP at the 139th base by shift-
ing the codon from GAA (Glu) to TGA (STOP). As a conse-
quence, the mutated gene is predicted to encode a protein
of just 46 amino acid residues, with only the first four of these
matching those of the wild-type 299 residue XLF protein (Fig-
ures 4C and 4D). This is therefore in line with our inability to
detect XLF protein in 2BN extracts and suggests strongly
that 2BN cells are functionally null for XLF. Nevertheless,
we note that there are alternative START codons down-
stream of the frameshift mutation, which in theory could
lead to the production of proteins corresponding to N-termi-
nally deleted forms of XLF (see Discussion).
Reintroduction of XLF into 2BN Cells Eliminates
Their Radiosensitivity
To test whether the severe radiosensitivity of 2BN cells was
indeed due to the XLFmutation, we established cell lines by
introducing the full-length wild-type XLF cDNA into 2BN cells
by genomic integration. The 2BN-C237 and 2BN-C231
clones thus generated were each derived from a single cell
colony and were indistinguishable from 2BN-hTERT cells in
morphology, growth rate, and in the levels of expression of
various proteins tested (Ligase IV, XRCC4, Tubulin, and
GAPDH; data not shown). In contrast to 2BN cells, however,
nuclear XLF was readily detected in 2BN-C237 and 2BN-
C231 cells (Figure 5A and data not shown). The level of
XLF protein expression in 2BN-C237 cells was approxi-
mately equivalent to that in various nonfibroblast human
cell lines studied (U2OS, HeLa, and 293T; data not shown)
although it was higher than that of MRC5 or BJ fibroblasts
(Figure 5B, top). Furthermore, and consistent with the data
from other cell lines, we found that Ligase IV was coimmuno-
precipitated with XLF from extracts of 2BN-C237 cells but
was not detected in immunoprecipitates from 2BN cells (Fig-
ure 5B, bottom). Most importantly, clonogenic survival as-
says after treating cells with varying doses of IR revealed
that 2BN-C237 and 2BN-C231 cells were dramatically less
radiosensitive than 2BN cells (Figure 5C and data not
shown). Indeed, following exposure to 2 Gy, less than 10%(E) Downregulation of XLF leads to a defect in chromosomal DSB repair. Ethidium bromide-stained pulsed-field gel electrophoresis of U2OS cells that had
been treated with the indicated siRNA oligonucleotides and irradiated 72 hr afterwards. Cells were irradiated for 40 min at 1.8 Gy/min on ice and left for the
indicated amount of time to repair at 37ºC. Then 100,000 cells were loaded per well and the gel was run at 33V, 50–5000 s linear switch time for 66 hr.
(F) Downregulation of XLF causes prolongation of histone H2AX phosphorylation after irradiation. Cells were transfected with XLFsi(1) or GFPsi and then
irradiated with 5 Gy of IR 72h afterwards. Extracts were prepared at the indicated time points and were analyzed by immunoblotting with mouse anti-phos-
pho-Ser 139 H2AX antibody.Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 307
Figure 4. 2BN Cell Line Derived from a Radiosensitive and Immune-Deficient Patient Possesses a Frameshift Mutation in the XLF
Gene, and XLF Protein Cannot Be Detected in These Cells
(A) Nuclear XLF is not detected by immunofluoresence staining of 2BN cells. Immunofluorescence microscopy of MRC5 (top), 2BN (middle), and BJ (bot-
tom) cells. Cells were stained with rabbit anti-XLF antibody, together with TOTO3 to detect DNA.
(B) No XLF is detectable in 2BN cells by immunoblotting. XLF protein levels in 293T, U2OS, 2BN, MRC5, and BJ cells. Fifty micrograms of RIPA-WCE were
analyzed by immunoblotting with rabbit anti-Ligase IV, rabbit anti-XRCC4, rabbit anti-XLF, and rat anti-tubulin antibodies, as indicated.
(C) XLFmRNA from 2BN cells harbors a frameshift mutation. Top: RT-PCRwith primers flanking the XLF open reading frame. cDNAwas prepared from total
mRNA derived from the indicated cell lines and subject to PCR analysis. Bottom: schematic representation of the XLFmRNA in wild-type (wt) and 2BN cells.
(D) In 2BN cells, the XLF gene is mutated. Top: schematic representation of the XLF gene (http://www.ensembl.org) and the first coding exon. Bottom:
chromatograms from sequencing reactions of XLF exon 11 in samples derived from MRC5 and 2BN cells, as indicated.of 2BN cells survived while 2BN-C237 and 2BN-231 cells,
much like normal fibroblasts (BJ) and U2OS cells, had a sur-
vival rate of 90%. These results therefore confirm that XLF
is critical for cellular resistance toward IR and moreover es-
tablish that the radiosensitivity of 2BN cells is caused by an
XLF defect.
XLF-Complemented 2BN Cells Are Proficient
in DNA DSB Repair
To establish whether the introduction of functional XLF into
2BN cells also corrected their DSB repair deficiency, we
studied the formation of phosphorylated histone H2AX
(gH2AX) in response to IR in 2BN and XLF-complemented308 Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc.2BN-C237 cells. We observed that noncomplemented
2BN cells had high background levels of gH2AX foci even
in the absence of irradiation, suggesting that they are unable
to effectively repair spontaneously arising DSBs. By contrast,
XLF complemented 2BN-C237 cells exhibited foci levels that
were equivalent to those of NHEJ-proficient MRC5 cells (Fig-
ures 5D and 5E and data not shown). Moreover, rates of
DSB repair as assessed by the disappearance of gH2AX
foci took place as effectively in 2BN-C237 cells as in
NHEJ-proficient MRC5 cells (Figure 5E). By contrast, 2BN
cells displayed high levels of IR-induced gH2AX foci, and
no reduction was observed in the first 6 hr of the time course
studied after irradiation (Figure 5E). These findings are
consistent with previous work showing that the NHEJ appa-
ratus plays a key role in DSB repair, particularly in the early
component of DSB repair events (Iliakis et al., 2004). Further-
more, they reveal that the NHEJ defect of 2BN cells is indeed
corrected by XLF expression. Nevertheless, we note that
that at longer time points after IR, the extent of gH2AX foci
did return to near background levels in all cells tested, sug-
gesting that even in 2BN cells many of the DSBs can even-
tually be repaired. Presumably this repair is independent of
the canonical end-joining process and is mediated by alter-
native DSB repair pathways irrespective of XRCC4, Ligase
IV, or XLF (Wang et al., 2005). Finally, and in accord with
the above data, we established by analysis of DSB repair
by pulsed-field gel electrophoresis that 2BN cells display
a defect in repairing IR-induced DSBs and that this defect
is corrected in XLF-complemented 2BN-C237 cells (Fig-
ure 5F, gel and graph). We therefore conclude that the
DSB repair defect of 2BN cells is a consequence of impaired
XLF function.
DISCUSSION
Here, we have described the identification of a previously un-
characterized protein, XLF, as a key component of the mam-
malian DNA NHEJ apparatus. Thus, we have shown that
cells downregulated for XLF display radiosensitivity and de-
fective DNA DSB repair. Furthermore, we have shown that
2BN cells derived from a radiosensitive human patient with
immune deficiencies contain a frameshift mutation in the
gene for XLF, and that the restoration of wild-type XLF ex-
pression to such cells corrects their DSB repair and radio-
sensitivity phenotypes. As reported elsewhere in this issue
of Cell, Buck et al. (2006) independently identified the
same gene, which they have given the name Cernunnos,
as being defective in a group of immune-deficient patients
with developmental abnormalities. Taken together, these
findings demonstrate that XLF/Cernunnos executes a crucial
function(s) in DNA NHEJ. In addition, they establish that in-
herited deficiency in XLF represents a new type of DNA repair
syndrome in man.
Although XLF could in principle influence NHEJ indirectly,
such as by modulating transcription or other aspects of cell
function in ways that facilitate NHEJ, our data strongly argue
that the effects of XLF on NHEJ are direct. We identified XLF
in a yeast two-hybrid screen for XRCC4 binding proteins and
subsequently verified this interaction by biochemical means.
Furthermore, we have found that XLF not only forms part of
this complex but is predicted to display structural similarity to
XRCC4. Based on these findings, it seems reasonable to
conclude that XLF promotes NHEJ at least in part by regulat-
ing the activity of the XRCC4-Ligase IV complex. In line with
this prediction, siRNA-mediated downregulation of XLF
yields radiosensitivity and NHEJ defects that are at least as
strong as those generated by depletion of XRCC4.
Howmight XLF functionally cooperate with the XRCC4-Li-
gase IV complex? While it is possible that XLF regulates the
stability or nuclear localization of XRCC4 and/or Ligase IV,
we feel that this is unlikely because XRCC4 and Ligase IVare still detected in the nucleus of XLF-deficient 2BN cells
(P.A., unpublished data). Instead, we favor a model in which
XLF promotes the DNA ligation function of the XRCC4-
Ligase IV complex. One attractive scenario, suggested by
the predicted structural homologies between XRCC4 and
XLF, is that XRCC4 principally functions with Ligase IV not
as an XRCC4 homomultimer but as an XRCC4-XLF hetero-
multimer. Such a model would be consistent with the obser-
vation that XRCC4, although essential for NHEJ in vivo, only
modestly enhances Ligase IV activity in vitro (Grawunder
et al., 1997; Modesti et al., 1999). It will hence be interesting
to study the effects of XLF on Ligase IV activity both in the ab-
sence or presence of XRCC4. Nevertheless, it is important to
note that XRCC4 and Ligase IV seem to be present at higher
levels in cells than XLF; and indeed, while we have found that
XLF is tightly associated with the XRCC4 complex in immu-
noprecipitation studies, not all cellular XRCC4 appears to be
bound to XLF (Figure 2). Supporting these observations, we
found that XLF cofractionates with a proportion of XRCC4
and Ligase IV upon size-exclusion chromatography at ap-
proximately 200 kDa (P.A., unpublished data), supporting
a model where XRCC4 (38 kDa), XLF (33 kDa), and Li-
gase IV (103 kDa) form one complex with the previously de-
scribed XRCC4:Ligase IV stochiometry of 2:1 (Modesti et al.,
2003). However, in these studies we have also observed an-
other population of XRCC4 and Ligase IV that fractionates in
higher-order complexes that are apparently XLF free. In this
regard, it is noteworthy that previous structural studies on
XRCC4 have indicated its potential to exist in both dimeric
and tetrameric states (Critchlow et al., 1997; Junop et al.,
2000; Lee et al., 2000; Modesti et al., 2003) and that there
are reasons to suppose that the tetrameric XRCC4 state
might be incompatible with the NHEJ functionality of its com-
plex with Ligase IV (Modesti et al., 2003; Sibanda et al.,
2001). It is therefore tempting to speculate that XLF binding
might alter the equilibrium between the twomultimeric states
of XRCC4, thus controlling Ligase IV activity. In regard to
these models, it will clearly be of interest to determine the
crystal structure of XLF both alone and in association with
XRCC4. Alternatively, or in addition, XLF might regulate the
access of the XRCC4-Ligase IV complex to DNA lesions.
In vitro XRCC4-Ligase IV does not preferentially bind to its
substrate, DNA ends, but has been shown to cooperatively
bind to large DNA fragments (Modesti et al., 1999). XLF
could therefore be required for XRCC4-Ligase IV recruitment
to DNA ends or could mediate recruitment, for example by
bridging the complex to other NHEJ components such as
Ku and DNA-PKcs. Recently, an elegant in vitro NHEJ sys-
tem has been developed in which XRCC4- and Ligase IV-de-
pendent end-joining takes place in the absence of XLF (Ma
et al., 2004). It will be of interest to see whether the inclusion
of XLF increases the NHEJ efficiency of such systems.
A key conclusion arising from our work is that an XLFmu-
tation causes the radiosensitivity and NHEJ defects of 2BN
cells, which are derived from a radiosensitive immune-
deficient patient. Thismutation leads to a translational frame-
shift at codon four in the XLF open reading frame, meaning
that the protein translated from this mRNAwould be severelyCell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 309
Figure 5. Reintroduction of Wild-Type XLF into 2BN Cells Eliminates Their Radiosensitivity and DSB Repair Defects
(A) Generation of a cell line derived from 2BN (clone 2BN-C237), where XLF was stably reintroduced into the genome, leads to the expression of nuclear XLF
protein. Immunofluorescence microscopy of 2BN (top) and XLF complemented 2BN-C237 (bottom) cells. Cells were stained with rabbit anti-XLF antibody
and TOTO3.
(B) XLF in 2BN-C237 cells interacts with Ligase IV. Top: immunoblot analysis of extracts prepared fromMRC5, BJ, 2BN, and XLF complemented 2BN-C237
cells. Bottom: coimmunoprecipitation of Ligase IV with XLF. XLF was precipitated from 500 mg of 2BN-C237 or 2BN extract with rabbit anti-XLF antibody.
Samples were analyzed by immunoblotting with rabbit anti-Ligase IV and rabbit anti-XLF antibody, as indicated. To prevent unspecific crossreactions be-
tween the rabbit antibodies, HRP-conjugated protein A was used as secondary reagent. Ten percent of input material was analyzed as a control.
(C) Cell lines derived from 2BN complemented with XLF are no longer radiosensitive. Clonogenic survival of 2BN (-), 2BN-C237 (:), BJ (X), and U2OS (B)
cells. Cells were treated with the indicated doses of IR. Data represent the mean and standard deviation of three independent experiments. For sake of
clarity, complemented 2BN-231 cells were omitted as they show identical survival to 2BN-237.
(D) Complementation of the DSB repair defect of 2BN cells by XLF, asmeasured by gH2AX foci formation. 2BN cells or complemented 2BN-C237 cells were
immunostained with anti-histone phospho-Ser 139 antibodies before or at the indicated times after treatment with 1Gy of IR.310 Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc.
truncated and would lack all of the evolutionarily conserved
regions of the protein. On face value, this suggests strongly
that 2BN cells and the patient from which they were derived
possess a fully inactivating mutation in the XLF gene; and in
line with this idea, we have been unable to detect XLF protein
expression in 2BN cells even when using the most sensitive
detection systems available. While these conclusions are not
a priori in conflict with current models for the physiological
functions of the NHEJ apparatus, the fact that the radiosen-
sitive patient giving rise to 2BN cells was overtly normal with
only mild developmental delay (Dai et al., 2003; P. Jeggo,
personal communication) is surprising in light of the general
consensus that full NHEJ deficiency is likely to be incompat-
ible with human viability. Indeed, despite targeted searches,
no loss-of-function mutations in the genes for Ligase IV or
XRCC4 have so far been described in human patients. Fur-
thermore, although several radiosensitive patients have been
identified bearing mutations in the gene for Ligase IV, in all
cases these appear to be hypomorphic conditions, with
the severity of the patient phenotype broadly reflecting the
extent to which Ligase IV function is disabled (O’Driscoll
et al., 2001). In addition, while the gene for Ligase IV has
been homozygously inactivated in a human pre-B cell line
to yield radiosensitive but viable cells (Grawunder et al.,
1998a), inactivation of the gene for XRCC4 or DNA Ligase
IV leads to early embryonic lethality in the mouse, at least
in part due to extensive apoptosis of newly generated post-
mitotic neurons in the developing nervous system (for review,
see Ferguson and Alt [2001]).
One possible explanation for the lack of lethality of the 2BN
mutation in man, therefore, is that the core NHEJ apparatus
is in fact not essential for mammalian viability. Support for
this idea is provided by the fact that components of the
Ku-DNA-PKcs complex, otherwise central to NHEJ, are
not required for viability in the mouse (for example, see Gu
et al. [1997], Nussenzweig et al. [1996], and Taccioli et al.
[1998]). Alternatively, it is possible that NHEJ is indeed
needed for mammalian viability but that the only really essen-
tial components of this pathway are XRCC4 and Ligase IV.
Finally, we note that we cannot at the present time rule out
the possibility that the 2BN mutation does not totally inacti-
vate XLF activity and that some XLF protein with residual
function is made from alternative, downstream translational
initiation codons in the mutated mRNA. Formal demonstra-
tion of whether or not XLF is needed for mammalian survival
will await the generation of knockout mice.
Over the past decade, it has become increasingly appar-
ent that inherited defects in DSB repair components can be
associated with enhanced predisposition to cancer, and that
such deficiencies—or somatically acquired mutations or epi-genetic silencing of the genes for DSB repair factors—can
affect the responses of patients and their tumors toward ra-
diotherapy and DNA-damaging chemotherapies. Although
the patient yielding the 2BN cells provides an extreme exam-
ple of radiation hypersensitivity arising from a defect in DSB
repair, it is tempting to speculate that more subtle mutations
or polymorphisms in XLF and other NHEJ components will
affect radiotherapy outcome at the more subtle level. Finally,
we note that loss or variation in XLF activity might contribute
toward cancer predisposition in the wider population.
EXPERIMENTAL PROCEDURES
Plasmids
GST-XLFwas created by PCR cloning in pGEX-4-TKP (Amersham), GFP-
XLF, FLAG-XLF, and HA-XLF were generated by PCR cloning into
pCDNA3.1+ (Invitrogen). For creation of the stable XLF complemented
cell line, full-length XLF was cloned in pBABE-puro.
Extract Preparation, Protein Expression, and Purifications
Mammalian whole-cell extracts were prepared in SDS sample buffer,
RIPA buffer, or EBC buffer (50 mM Tris-HCl [pH 7.5]; 120 mM NaCl;
0.5% NP-40; 1 mM dithiothreitol; 1 mM AEBSF; 1 mMNaF; 1 mM b-glyc-
erophosphate; 10 mg/ml Leupeptin). HNE was from Computer Cell Cul-
ture Center. Recombinant XLF protein was synthesized in E. coli BL21
(Novagen) and was purified to near homogeneity by glutathione Sephar-
ose affinity chromatography (Amersham).
GST Pull-Downs and Immunoprecipitations
Immunoprecipitations and GST pull-downs were done as described be-
fore (Goldberg et al., 2003). Recombinant GST-XLF bound to glutathione
Sepharose (Amersham) was incubatedwith precleared HNE for 4 hr in the
presence of 50 mg/ml ethidium bromide and washed five times with EBC
buffer before resuspension in SDS sample buffer. Immunoprecipitations
were done with Protein A and Protein G Sepharose for rabbit polyclonal
and mouse monoclonal antibodies, respectively. Lysates including
20 mg/ml ethidium bromide were precleared with the respective beads
and subsequently incubated overnight with 1 mg of antibody (or 1 ml of se-
rum). Complexes were precipitated with beads for 1 hr and washed five
times with EBS buffer before resuspension in SDS sample buffer.
RT-PCR and Genomic Sequencing
Total RNA was prepared using High Pure RNA Isolation Kit (Roche) ac-
cording to manufacturer’s instructions. cDNA was synthesized using
the cDNA synthesis kit (Roche) according to manufacturer’s instructions.
Total genomic DNA was prepared by boiling lysis. PCR reactions were
carried out using the High Fidelity PCR Kit (Roche). PCR products were
sequenced directly as well as cloned into pCR-Blunt II-Topo (Invitrogen)
to improve reading. Sequencing reactions were done by the Department
of Biochemistry DNA sequencing facility (Cambridge, United Kingdom).
Yeast Two-Hybrid Screen
Yeast-two hybrid screening was performed with pLexA-dir encoding full-
length XRCC4 as a bait construct, screening a pACT2 human brain library
(complexity: 3.5E6). The screen was carried out in collaboration with Du-
alsystems (Zurich, Switzerland).(E) Complementation of 2BN cells with XLF changes the kinetics of H2AX phosphorylation back to that of wild-type cells. Statistical analysis of phospho-H2A
foci formation in MRC5, 2BN, and 2BN-C237 cells at the indicated time points after 1 Gy of IR treatment. At least 100 cells were counted per time point, and
the data represent mean and standard deviation of two independent experiments.
(F) Complementation of 2BN cells with XLF eliminates their defect in chromosomal DSB repair. PFGE of 2BN and 2BN-C237 cells. Cells were irradiated for
40min at 1.8 Gy/min on ice and left for the indicated amount of time to repair at 37ºC. Then100,000 cells were loaded per well and the gel was run at 33V,
50–5000 s linear switch time for 66 hr. Left: representative ethidium bromide-stained gel. Right: released DNA was quantified by using MacBAS image
analysis. Data represent percentage of DNA released relative to DNA release directly after irradiation. Error bars represent mean and standard deviation
of two independent experiments.Cell 124, 301–313, January 27, 2006 ª2006 Elsevier Inc. 311
Cell Culture
293T and U2OS cells were cultured in DMEM containing 10% serum.
2BNhTERT (2BN, a gift from P. Jeggo; Dai et al., 2003), 2BN-C237,
2BN-C231, MRC5hTERT (MRC5), and BJhTERT (BJ) cells were cultured
inDMEMcontaining 15%serum.Complementation of 2BNcellswasdone
by transfection of linearized pBabe-puro plasmid encoding wild-type XLF,
followed by selection with puromycin. Single-cell colonies were isolated
and expanded. Transfection of plasmids and siRNA duplexes was done
with either FuGene6 (Roche) or calciumphosphate andoligofectamine (In-
vitrogen), respectively. The luciferase- (CGUACGCGGAAUACUUCGAdT
dT) and GFP-targeting (GGCUACGUCCAGGAGCGCACCdTdT) siRNA
duplexes were from Dharmacon. XLF (1, GCAUUACAGUGCCAAGUGA
dTdT), (2, CGCUGAUUCGAGAUCGAUUGAdTdT) and XRCC4 (AUAUGU
UGGUGAACUGAGAdTdT) targeting siRNA duplexes were synthesized
by MWG-Biotech. X-ray irradiation and clonogenic survival assays were
done as previously described (Goldberg et al., 2003). Random plasmid in-
tegration was done by transfection of linearized pEYFP-Nuc expression
plasmid. Twenty-four hours later, cells were replated at low density in
G418-containingmedium, and colonieswere counted 10days after trans-
fection. A fraction of the transfected cells was monitored for nuclear YFP
expression to normalize the data for transfection efficiency.
Antibodies and Immunofluorescence
Commercial antibodies used in this study were from Abcam (XRCC4, Tu-
bulin), Upstate (gH2AX), SIGMA (anti-FLAG M2, rabbit anti-HA), Roche
(HA-Peroxidase 3F10), and Genetex (mouse XRCC4). Monoclonal anti-
GFP and anti-HA antibodies were from Cancer Research UK. Rabbit an-
tiserum recognizing human Ligase IV and MRE11 have been described
before (Critchlow et al., 1997; Goldberg et al., 2003). Anti-human-XLF an-
tibody was raised for this study against purified recombinant GST-XLF,
characterized, and affinity purified. For immunofluorescence staining,
cells were grown on glass coverslips and fixed in 3.5% paraformaldehyde
for 12 min. Fixed cells were washed briefly with PBS + 0.5% Triton-X100
and stained with antibodies as indicated. Analysis of IRIF was performed
as described before (Goldberg et al., 2003; Kuhne et al., 2004). At least
100 cells were scored per time point per experiment.
Pulsed-Field Gel Electrophoresis
PFGE was done as described before (Kuhne et al., 2004). Cells were har-
vested and 100,000 cells were embedded in 0.5% low-melting aga-
rose. Plugs were incubated overnight at 55ºC in 500 ml lysis buffer
(50 mM Tris [pH 8.0], 50 mM EDTA [pH 8.0], 2% sarcosyl, 2 mg/ml pro-
teinase) and washed twice with 1 ml of TE at room temperature. Electro-
phoresis of the prepared samples was performed using the Gene Naviga-
torTM system (Amersham Biosciences). Electrophoretic conditions were
as indicated.
Supplemental Data
Supplemental Data include one figure and one table and can be found
with this article online at http://www.cell.com/cgi/content/full/124/2/
301/DC1/.
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